These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17244110

  • 1. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis.
    Goodman WG.
    Semin Dial; 2007; 20(1):1-4. PubMed ID: 17244110
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. [Bone and bone related biochemical examinations. Hormone and hormone related substances. Parathyroid hormone].
    Tanaka M, Fukagawa M.
    Clin Calcium; 2006 Jun; 16(6):927-34. PubMed ID: 16751687
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management.
    Cantor T.
    Semin Dial; 2005 Jun; 18(5):359-64. PubMed ID: 16191171
    [Abstract] [Full Text] [Related]

  • 6. Immunoassays for the detection of parathyroid hormone.
    Jüppner H, Potts JT.
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N81-6. PubMed ID: 12412782
    [Abstract] [Full Text] [Related]

  • 7. Critical issues of PTH assays in CKD.
    Komaba H, Goto S, Fukagawa M.
    Bone; 2009 Apr; 44(4):666-70. PubMed ID: 19159701
    [Abstract] [Full Text] [Related]

  • 8. An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease.
    Savoca R, Bock A, Kraenzlin ME, Schmid HR, Huber AR.
    Clin Chim Acta; 2004 May; 343(1-2):167-71. PubMed ID: 15115690
    [Abstract] [Full Text] [Related]

  • 9. [Clinical significance of PTH (1-84) and PTH (7-84) in patients with predialysis chronic renal failure in relation to bone metabolism markers].
    Tsuchida T, Ishimura E, Hirowatari K, Matsumoto N, Jono S, Miki T, Inaba M, Nishizawa Y.
    Clin Calcium; 2005 Sep; 15 Suppl 1():156-60; discussion 160. PubMed ID: 16272650
    [Abstract] [Full Text] [Related]

  • 10. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F.
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [Abstract] [Full Text] [Related]

  • 11. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 12. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M, Kazama J, Shigematsu T.
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship between serum parathyroid hormone and trace elements (serum zinc and magnesium) in hemodialyzed chronic renal failure children.
    El Tayeb AA, Abd El-Mottaleb NA, Abdel Aziz EA.
    Biol Trace Elem Res; 2009 May; 128(2):128-34. PubMed ID: 18972069
    [Abstract] [Full Text] [Related]

  • 15. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W.
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [Abstract] [Full Text] [Related]

  • 16. Differences between serum and plasma for intact parathyroid hormone measurement in patients with chronic renal failure in routine clinical practice.
    Twomey PJ, Whitlock T, Pledger DR.
    J Clin Pathol; 2005 Sep; 58(9):1000-1. PubMed ID: 16126890
    [Abstract] [Full Text] [Related]

  • 17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Sep; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 18. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL.
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [Abstract] [Full Text] [Related]

  • 19. Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism.
    Kazama JJ, Omori K, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F, Iwasaki Y, Fukagawa M.
    Ther Apher Dial; 2006 Jun; 10(3):262-6. PubMed ID: 16817791
    [Abstract] [Full Text] [Related]

  • 20. Serum level of intact parathyroid hormone and other markers of bone metabolism in dialyzed patients.
    Grzegorzewska AE, Młot-Michalska M.
    Adv Perit Dial; 2007 Jun; 23():162-5. PubMed ID: 17886625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.